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European Association for the Study of the Liver⇑Summary with acute liver failure. Wilson’s disease is not just a disease ofThis Clinical Practice Guideline (CPG) has been developed to
assist physicians and other healthcare providers in the diagnosis
and management of patients with Wilson’s disease. The goal is to
describe a number of generally accepted approaches for diagno-
sis, prevention, and treatment of Wilson’s disease. Recommenda-
tions are based on a systematic literature review in the Medline
(PubMed version), Embase (Dialog version), and the Cochrane
Library databases using entries from 1966 to 2011. The Grades
of Recommendation, Assessment, Development, and Evaluation
(GRADE) system used in other EASL CPGs was used and set
against the somewhat different grading system used in the
AASLD guidelines (Table 1A and B). Unfortunately, there is not
a single randomized controlled trial conducted in Wilson’s dis-
ease which has an optimal design. Thus, it is impossible to assign
a high or even a moderate quality of evidence to any of the ques-
tions dealt with in these guidelines. The evaluation is mostly
based on large case series which have been reported within the
last decades.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Normal dietary consumption and absorption of copper exceed
the metabolic need, and homeostasis of this element is main-
tained exclusively by the biliary excretion of copper. Wilson’s dis-
ease is an inherited disorder in which defective biliary excretion
of copper leads to its accumulation, particularly in liver and brain
[1,2]. Wilson’s disease is due to mutations of the ATP7B gene on
chromosome 13 [3,4], which encodes a copper-transporting
P-type ATPase (ATP7B) residing in the trans-Golgi network of
hepatocytes. ATP7B is responsible for transporting copper from
intracellular chaperone proteins into the secretory pathway, both
for excretion into bile and for incorporation into apo-ceruloplas-
min for the synthesis of functional ceruloplasmin [3,4]. The
development of Wilson’s disease is due to the accumulation of
copper in affected tissues.
Clinical presentation can vary widely, but the key features of
Wilson’s disease are liver disease and cirrhosis, neuropsychiatric
disturbances, Kayser–Fleischer rings in Desçemet’s membrane of
the cornea, and acute episodes of hemolysis often in associationJournal of Hepatology 20
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Wilson’s disease is a genetic disorder that is found worldwide.
Wilson’s disease is recognized to be more common than previ-
ously thought, with a gene frequency of 1 in 90–150 and an inci-
dence (based on adults presenting with neurologic symptoms
[6]) that may be as high as 1 in 30,000 [7]. More than 500 distinct
mutations have been described in the Wilson gene, from which
380 have a conﬁrmed role in the pathogenesis of the disease [8].Clinical presentation
The most common presentations are with liver disease or neuro-
psychiatric disturbances. Asymptomatic patients are most often
detected by family screening.
Age at onset of symptoms
Wilson’s disease may present symptomatically at any age,
although the majority presents between ages 5 and 35. The youn-
gest patient reported with cirrhosis due to Wilson’s disease was
3-years-old [9]. About 3% of patients present beyond the fourth
decade, either with hepatic or neurologic disease [5]. The oldest
patients diagnosed were in their eighth decade [10,11].
Physical signs
The clinical hallmark of Wilson’s disease is the Kayser–Fleischer
ring, which is present in 95% of patients with neurologic
symptoms and somewhat over half of those without neurologic
symptoms [12,13]. In children presenting with liver disease,
Kayser–Fleischer rings are usually absent [14]. Kayser–Fleischer
rings are caused by deposition of copper in Desçemet’s mem-
brane of the cornea. A slit-lamp examination by an experienced
observer is required to identify Kayser–Fleischer rings. They are
not entirely speciﬁc for Wilson’s disease, since they may be found
in patients with chronic cholestatic diseases including children
with neonatal cholestasis. Other ophthalmologic changes are rare
and include sunﬂower cataracts, which are caused by deposits of
copper in the center of the lens. They can also be found by slit-
lamp examination [15].
Neurologic signs are variable, most often tremor, ataxia, and
dystonia. Signs of liver disease are nonspeciﬁc, but any liverContributors: Chairman: Peter Ferenci. Clinical Practice Guidelines Members: Anna
Czlonkowska, Wolfgang Stremmel, Roderick Houwen, William Rosenberg, Michael
Schilsky. EASL Governing Board Representatives: Peter Jansen and Darius Morad-
pour. Reviewer(s): Jonathan Gitlin.
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Table 1. (A) GRADE system as used in EASL Clinical Practice Guidelines [159].
(B) System of Recommendations as used in AASLD Practice Guidelines [130].
Grade Evidence
I Randomized controlled trials
II-1 Controlled trials without randomization
II-2 Cohort or case-control analytic studies
II-3 Multiple time series, dramatic uncontrolled 
experiments
III Opinions of respected authorities, descriptive 
epidemiology
Evidence Description
High 
quality
Further research is very unlikely to 
change our confidence in the estimated 
effect
A
Moderate 
quality
Further research is likely to have an 
important impact on our confidence in
important impact on our confidence 
the estimate effect and may change the 
estimate
B
Low 
quality
Further research is likely to have an 
in the estimate effect and is likely to 
change the estimate. Any change of 
estimate is uncertain
Factors influencing the strength of
C
Recommendation
Strong
recommendation included the quality of 
evidence, presumed patient-important 
outcomes and costs
1
Weak Variability in preferences and values, or 
more uncertainty. Recommendation is 
made with less certainty, higher costs or 
resource consumption
2
DescriptionClassification
Class I Conditions for which there is evidence and/or 
general agreement that a given procedure or 
Conditions for which there is conflicting evidence
ness/efficacy of a procedure or treatment
treatment is beneficial, useful, and effective
Class II
and/or a divergence of opinion about the useful-
Class IIa Weight of evidence/opinion is in favor of 
usefulness/efficacy
Class IIb
evidence/opinion
Usefulness/efficacy is less well established by
Class III Conditions for which there is evidence and/or 
general agreement that a procedure/treatment is 
not useful/effective and in some cases may be 
harmful.
Level of 
evidence Description
Level A Data derived from multiple randomized clinical 
trials or meta-analyses
Level B Data derived from a single randomized trial, or 
nonrandomized studies
Level C Only consensus opinion of experts, case studies, 
or standard of care
A
B
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672 Journal of Hepatology 201disease of unknown origin should be considered as Wilson’s dis-
ease until proved otherwise. Diagnostic vigilance is important
because Kayser–Fleischer rings may be absent in up to 50% of
patients with Wilson’s disease affecting the liver [12].
Liver disease
Any type of liver disease may be encountered in patients with
Wilson’s disease. Clinically evident liver disease may precede
neurologic manifestations by as much as 10 years and most
patients with neurologic symptoms have some degree of liver
disease at presentation. Presenting symptoms of liver disease
can be highly variable, ranging from asymptomatic, with only
biochemical abnormalities, to overt cirrhosis with all its compli-
cations. Wilson’s disease may also present as acute hepatic failure
sometimes associated with Coombs-negative hemolytic anemia
and acute renal failure. Patients diagnosed with Wilson’s disease
who have a history of jaundice may have previously experienced
an episode of hemolysis. Clinical symptoms are summarized in
Table 2.
Acute liver failure due to Wilson’s disease (former: ‘‘fulminant
Wilson’s disease’’)
Wilson’s disease enters into the differential diagnosis of any
young patient presenting with acute hepatitis. Its clinical presen-
tation may be indistinguishable from that of acute viral hepatitis,
with jaundice and abdominal discomfort. In some patients
symptoms resolve spontaneously, but once the diagnosis is made,
lifelong treatment is necessary. On the other hand, rapid deterio-
ration can occur with acute liver failure.
Wilson’s disease accounts for 6–12% of all patients with acute
liver failure who are referred for emergency transplantation
[16,17]. Although cirrhosis is already present in most cases, the
clinical presentation is acute and progresses rapidly to hepatic
and renal failure and, when untreated, carries an almost 95%
mortality. Acute liver failure due to Wilson’s disease occurs pre-
dominantly in young females (female:male ratio 4:1) [18]. An
acute presentation with rapid deterioration may also occur in
patients who were previously treated but stopped their medica-
tions [16]. Suspicion for acute Wilson’s disease should be partic-
ularly high in patients with deep jaundice, low haemoglobin, low
cholinesterase [17], only mildly increased transaminases, and low
alkaline phosphatase.
Chronic hepatitis and cirrhosis
Many patients present with signs of chronic liver disease and evi-
dence of cirrhosis, either compensated or decompensated.
Patients may present with isolated splenomegaly due to clinically
inapparent cirrhosis with portal hypertension. The presentation
may be indistinguishable from other forms of chronic active hep-
atitis, with symptoms including jaundice, malaise, and vague
abdominal complaints.
Hemolysis
Coombs-negative haemolytic anemia may be the only initial
symptom of Wilson’s disease. However, marked hemolysis is
commonly associated with severe liver disease. Decay of liver
cells may result in the release of large amounts of stored copper,
which further aggravates hemolysis. In one series, hemolysis was
a presenting feature in 25 out of 220 cases (12%); in these
patients hemolysis occurred either as a single acute episode or2 vol. 56 j 671–685
Table 2. Clinical symptoms in Wilson’s disease patients presenting with liver disease.
Author,   
Country, [Ref.]
Walshe,  
UK, [157]
Stremmel et al.,
Germany, [39]
Schilsky et al.,
USA, [142]
Scott et al.,
UK, [158]
Ferenci,
Austria, [44]
N with liver disease 
(out of)
87       
(>250)
n.a.
(51)
20*       
(320)
17*         
(45)
30          
 (64)
Presenting symptom
Jaundice, anorexia, vomiting (%) 44 14 15 41 37
Ascites/edema (%) 26 14 50 24 23
Variceal hemorrhage (%) 6 10 6 3
Hemorrhagic diathesis (%) 8 3
Hemolysis (%) 20 10 5 10
Hepatomegaly/splenomegaly (%) 16 49 15 29 17
Acute liver failure (%) n.a. n.a. n.a. n.a. 17
Asymptomatic$ (%) 18 5 23
⁄Only cases with chronic active hepatitis.
$Elevated ALT at routine testing, or accidental ﬁnding of cirrhosis or of Kayser–Fleischer rings.
JOURNAL OF HEPATOLOGYrecurrently or was low-grade and chronic [18]. In a series of 283
Japanese patients with Wilson’s disease, only three presented
with acute hemolysis alone [19]. One quarter of the patients pre-
senting with jaundice also had hemolysis. Acute liver disease and
hemolysis as a presenting symptom can occur during delivery,
mimicking HELLP syndrome [20]. Low-grade hemolysis may be
associated with Wilson’s disease even when liver disease is not
clinically evident. Some patients presenting with neurologic
symptoms report that they have experienced transient episodes
of jaundice previously, probably due to hemolysis [21]. On the
other hand, rapid deterioration can occur with acute liver failure.Neurologic disease
Wilson’s disease can manifest with an impressive spectrum of
neurological, behavioral or psychiatric disorders, which may be
its ﬁrst clinical manifestation, appearing simultaneously with
hepatic signs, or some years later.
Neurological presentation can be extremely subtle, and inter-
mitted for many years, but may also develop very rapidly, leading
within a few months to complete disability. The neurological
abnormalities can be classiﬁed as: (1) Akinetic-rigid syndrome
similar to Parkinson’s disease; (2) Pseudosclerosis dominated by
tremor; (3) Ataxia; and (4)Dystonic syndrome. Inmany cases, neu-
rological signs are very difﬁcult to classify as patients can have
more than one abnormality, each with different levels of severity.
The characteristic tremor is a coarse, irregular proximal trem-
ulousness with a ‘‘wing beating’’ appearance. Dystonia can be
focal, segmental or very severe, involving all parts of the body,
leading to severe contractures. Very common motor impairments
involve the cranial region, and manifest clinically as dysarthria
(can be cerebellar or extrapyramidal leading to aphonia), drooling
or oropharyngeal dystonia. Facial grimacing, open jaw, running
saliva, and lip retraction are characteristic manifestations. Speech
changes and drooling are often early neurologic symptoms. A tre-
mor-rigidity syndrome (‘‘juvenile Parkinsonism’’) should raise
suspicion of Wilson’s disease [22–24].
Because of an increasing difﬁculty in controlling movement or
progressive dystonia, patients become bedridden and unable to
care for themselves. Ultimately, the patient becomes severely dis-
abled, usually alert, but unable to talk. In patients presentingJournal of Hepatology 201with advanced liver disease, neurologic symptoms can be mis-
taken for signs of hepatic encephalopathy.
Psychiatric symptoms
Behavioral and psychiatric symptoms are common and some of
them may precede neurologic or hepatic signs and symptoms.
About one-third of patients initially present with psychiatric
abnormalities. In children with Wilson’s disease, declining school
performance, personality changes, impulsiveness, labile mood,
sexual exhibitionism, and inappropriate behavior are observed
[24,25]. The initial symptoms are frequently misdiagnosed as
behavioral problems associated with puberty. In older persons,
psychotic features resembling paranoia, schizophrenia or depres-
sion can be observed but behavioral changes are also common.
Severe cognitive deterioration is observed in patients with
advanced neurological disease, but in general, cognitive function
is not markedly impaired [26].
A delay in diagnosing Wilson’s disease in patients with neuro-
psychiatric presentations is frequent and was in one case as long
as 12 years [27]. Patients presenting with neuropsychiatric symp-
toms may have concurrent symptomatic liver disease, but in
most patients liver disease can only be detected by laboratory
evaluation, imaging studies of the liver or by liver histology.
About half of the patients have advanced ﬁbrosis or frank cirrho-
sis. On the other hand, signs of liver disease may be even com-
pletely absent at biopsy [28].
Other clinical manifestations
Less common presentations include gigantism, lunulae, renal
abnormalities including aminoaciduria and nephrolithiasis,
hypercalciuria and nephrocalcinosis [29,30], cardiomyopathy
[31], myopathy [32], chondrocalcinosis and osteoarthritis [33],
hypoparathyroidism [34], pancreatitis [35], infertility or repeated
miscarriages [36,37].Prognosis
UntreatedWilson’s disease is universally fatal, with most patients
dying from liver disease and a minority from complications of2 vol. 56 j 671–685 673
Table 3. Prognostic index in Wilson’s disease [40], modiﬁed by Dhawan et al.
[41].
1* 2*  3* 4*
Serum bilirubin 
(µmol/L)
100-150 151-200 201-300 >300
AST (U/L) 100-150 151-300 301-400 >400
INR 1.3-1.6 1.7-1.9 2.0-2.4 >2.4
WBC [109/L] 6.8-8.3 8.4-10.3 10.4-15.3  >15.3
Albumin [g/L] 34-44 25-33 21-24 <21
⁄= score points, upper limit of normal for AST = 20 IU/ml (at King’s College). A
score P11 is associated with high probability of death without liver
transplantation.
Clinical Practice Guidelinesprogressive neurologic disease. With chelation treatment and
liver transplantation, prolonged survival has become the norm
[27,38,39], although mortality has not been assessed prospec-
tively. In general, prognosis for survival depends on the severity
of liver and neurological disease and compliance with drug treat-
ment. Liver function becomes normal over 1–2 years of treatment
in most patients with no or compensated cirrhosis at presenta-
tion, and then remains stable without progressive liver disease
with adherence to treatment. At the other end of the spectrum,
medical therapy is rarely effective in patients presenting with
acute liver failure due to Wilson’s disease, mainly due to the time
required to remove toxic copper from the organism. A prognostic
index has been developed [40], and later modiﬁed by Dhawan
et al. [41]. A score greater than 11 is always fatal without liver
transplantation (Table 3). Patients presenting with neurologic
symptoms fare better with respect to life expectancy, especially
if liver disease is limited. However, neurologic symptoms appear
to be only partly reversible with treatment and may even worsen
following initiation of treatment.
In patients undergoing orthotopic liver transplantation, sur-
vival may be slightly reduced early on, but appears normal (for
transplant population) thereafter [42].Differential diagnosis
Acute hepatitis with Wilson’s disease presents similarly to any
other acute cases of hepatitis. Similarly, Wilson’s disease shouldTable 4. Routine tests for diagnosis of Wilson’s disease.
Test False “negative”
Serum ceruloplasmin Decreased by 50% of 
lower normal value Overestimation by imm
Pregnancy, estrogen t
24-hour urinary copper >1.6 µmol/24 h    
>0.64 µmol/24 h in 
children
Normal:
- incorrect collection
- children without liver 
Serum “free” copper >1.6 µmol/L Normal if ceruloplasmi
Hepatic copper >4 µmol/g dry weight Due to regional variati
- in patients with active
- in patients with regen
Kayser-Fleischer rings 
by slit lamp 
examination
Present Absent 
- in up to 50% of patie
- in most asymptomati
Typical finding
Normal levels in patien
674 Journal of Hepatology 201enter into the diagnosis of all patients with chronic hepatitis
and cirrhosis, as routine histologic changes are nonspeciﬁc.
Wilson’s disease should be considered when acute hepatitis is
accompanied by rapid onset of jaundice and hemolytic anemia.
During adolescence, Wilson’s disease presenting with neurologic
symptoms may be misdiagnosed as a behavioural problem
because initial symptoms may be subtle. More advanced move-
ment disorders in a young person should provoke consideration
of Wilson’s disease, but the diagnosis may be overlooked where
the presentation suggests a primarily psychological or psychiatric
disorder.Diagnostic methods
Typically, the combination of Kayser–Fleischer rings and a low
serum ceruloplasmin (<0.1 g/L) level is sufﬁcient to establish a
diagnosis. When Kayser–Fleischer rings are not present (as is
common in the hepatic manifestation of Wilson’s disease), ceru-
loplasmin levels are not always reliable because they may be low
for reasons other than Wilson’s disease (e.g. autoimmune hepati-
tis, severe hepatic insufﬁciency in advanced liver disease, celiac
disease, familial aceruloplasminemia) [43] or in heterozygous
carriers of ATP7B mutations who do not show copper overload
disease. On the other hand, inﬂammation in the liver or else-
where may cause the ceruloplasmin concentration to rise to nor-
mal levels, reﬂecting its identity as an acute phase protein. This is
also true for treatment with estrogens. Thus, for many patients, a
combination of tests reﬂecting disturbed copper metabolism may
be needed. Not a single test is per se speciﬁc and, thus, a range of
tests has to be applied (Table 4). A diagnostic score based on all
available tests was proposed by the Working Party at the 8th
International Meeting on Wilson’s disease, Leipzig 2001 [44]
(Table 5). The Wilson’s disease scoring system provides a good
diagnostic accuracy [45]. The diagnostic algorithm based on this
score is shown in Fig. 1.
Serum ceruloplasmin
Ceruloplasmin is the major carrier of copper in the blood. It
contains six copper atoms per molecule (holoceruloplasmin)
but may be present just as the protein without the copperFalse “positive”
unologic assay
herapy
Low levels in:
- malabsorption
- aceruloplasminemia
- heterozygotes
disease
Increased:
- hepatocellular necrosis
- cholestasis 
- contamination
n overestimated by immunologic assay
on
 liver disease
erative nodules
Cholestatic syndromes
nts with hepatic Wilson’s disease 
c siblings
Primary biliary cirrhosis
ts with marked hepatic inflammation
2 vol. 56 j 671–685
Table 5. Scoring system developed at the 8th International Meeting on Wilson’s disease, Leipzig 2001 [44].
Typical clinical symptoms and signs
KF rings
Present 2
Absent 0
Neurologic symptoms**
Severe 2
Mild 1
Absent 0
Serum ceruloplasmin
Normal (>0.2 g/L) 0
0.1-0.2 g/L 1
<0.1 g/L 2
Coombs-negative hemolytic anemia
Present 1
Absent        0
Other tests
Liver copper (in the absence of cholestasis)
>5x ULN (>4 µmol/g) 2
0.8-4 µmol/g 1
Normal (<0.8 µmol/g) -1
Rhodanine-positive granules* 1
Urinary copper (in the absence of acute hepatitis) 
Normal 0
1-2x ULN 1
>2x ULN 2
Normal, but >5x ULN after D-penicillamine 2
Mutation analysis
On both chromosomes detected 4
On 1 chromosome detected 1
No mutations detected 0
TOTAL SCORE Evaluation:
4 or more Diagnosis established
3 Diagnosis possible, more tests needed
2 or less Diagnosis very unlikely
⁄If no quantitative liver copper available, ⁄⁄or typical abnormalities at brain magnetic resonance imaging. KF, Kayser–Fleischer; ULN, upper limit of normal.
JOURNAL OF HEPATOLOGY(apoceruloplasmin). Ceruloplasmin is an acute phase reactant
possessing a ferroxidase activity [46]. Levels of serum ceruloplas-
min may be measured enzymatically by its copper-dependent
oxidase activity towards speciﬁc substrates, or by antibody-
dependent assays such as radioimmunoassay, radial immunodif-
fusion, or nephelometry. Immunologic assays may overestimate
ceruloplasmin concentrations since they do not discriminate
between apoceruloplasmin and holoceruloplasmin. The normal
concentration of ceruloplasmin measured by the enzymatic assay
varies among laboratories (with a lower limit between 0.15 and
0.2 g/L). In Wilson’s disease, it is usually lower than 0.1 g/L.
Serum ceruloplasmin concentrations are elevated by acute
inﬂammation, in states associated with hyperestrogenemia such
as pregnancy and estrogen supplementation. Serum ceruloplas-Typical clinical symptoms
(extra pyramidal symptoms, KFR, CPL)
Score 0-1 Score 2-3 Score ≥4
Mutation analysis
2 mutations
1 mutation
0 mutation
Score ≤3
Diagnosis
established
Urinary copper
>1.6 µmol/d*
Hepatic copper
>4 µmol/g
Normal or <4 µmol/g
Urinary copper
>1.6 µmol/d*
Fig. 1. Diagnostic algorithms for Wilson’s disease based on the Leipzig Score
[44]. ⁄In children the cut off can be lowered to 0.64 lmol/d.
Journal of Hepatology 201min is typically decreased in patients with neurologic Wilson’s
disease, but may be in the low normal range in about half of
patients with active Wilson’s liver disease. On the other hand,
serum ceruloplasmin may be low in other conditions with
marked renal or enteric protein loss, malabsorption syndromes
or with severe end-stage liver disease of any etiology. Approxi-
mately 20% of heterozygotes have decreased levels of serum
ceruloplasmin [1,47]. Patients with aceruloplasminemia lack
the protein entirely due to mutations in the ceruloplasmin gene
on chromosome 3. These patients may exhibit hemosiderosis
but do not have copper accumulation [48]. Thus, serum cerulo-
plasmin alone is not sufﬁcient to diagnose or to exclude Wilson’s
disease. A prospective study on serum ceruloplasmin, as a screen-
ing test for Wilson’s disease in patients referred with liver dis-
ease, showed that subnormal ceruloplasmin had a positive
predictive value of only 6%. In children with Wilson’s disease,
15–36% had ceruloplasmin in the normal range [14,49]. In one
series, 12 out of 55 Wilson’s disease patients had normal cerulo-
plasmin and no Kayser–Fleischer rings [12]. The predictive value
of ceruloplasmin for diagnosis of Wilson’s disease in acute liver
failure is poor [50]. In one recently published study, measure-
ment of serum ceruloplasmin oxidase activity was superior to
immunologic assays for diagnosing Wilson’s disease, but these
assays are generally not available in routine labs [51].
Serum copper
Although a disease of copper overload, the total serum copper
(which includes copper incorporated in ceruloplasmin) in
Wilson’s disease is usually decreased in proportion to the
decreased ceruloplasmin in the circulation. In patients with
severe liver injury, serum copper may be within the normal
range, independent of whether serum ceruloplasmin levels are
elevated or low. In the setting of acute liver failure due to
Wilson’s disease, levels of serum copper may even be markedly2 vol. 56 j 671–685 675
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elevated due to the sudden release of the metal from liver tissue
stores. Normal or elevated serum copper levels, in the face of
decreased levels of ceruloplasmin, indicate an increase in the
concentration of copper which is not bound to ceruloplasmin in
the blood (non-ceruloplasmin-bound copper). Non-ceruloplas-
min-bound copper (or ‘‘free copper’’) can be calculated by sub-
tracting ceruloplasmin-bound copper (3.15  ceruloplasmin in
mg/L equals the amount of ceruloplasmin-bound copper in lg/
L) from the total serum copper concentration (in lg/L; serum
copper in lmol/L  63.5 equals serum copper in lg/L) [52]. The
serum non-ceruloplasmin-bound copper concentration has been
proposed as a diagnostic test for Wilson’s disease [53]. In most
untreated patients, it is elevated above 200 lg/L. The serum
non-ceruloplasmin copper concentration may be elevated in
acute liver failure of any etiology, in chronic cholestasis [54],
and in cases of copper intoxication. The major problem with
non-ceruloplasmin-bound copper as a diagnostic test for Wilson’s
disease is that it is dependent on the adequacy of the methods for
measuring both serum copper and ceruloplasmin. It is of more
value in monitoring pharmacotherapy than in the diagnosis of
Wilson’s disease.
Urinary copper excretion
The amount of copper excreted in the urine in a 24-hour period
may be helpful for diagnosing Wilson’s disease and for monitor-
ing treatment. In untreated patients, the 24-hour urinary excre-
tion of copper reﬂects the amount of non-ceruloplasmin-bound
copper in the circulation. The exact urine volume and the total
creatinine excretion per 24 h are important for accurate determi-
nation of urinary copper excretion. In case of renal failure, the
test is not applicable. In untreated symptomatic patients, ‘‘base-
line’’ copper excretion greater than 1.6 lmol/24 h (100 lg/24 h)
is taken as diagnostic of Wilson’s disease [5]. However, basal
24-hour urinary copper excretion may be less than 1.6 lmol/
24 h at presentation in 16–23% of patients, especially in children
and asymptomatic siblings [12,14,55]. Since urinary copper
excretion is negligible in healthy individuals [56], a urinary cop-
per excretion above 0.64 lmol/24 h can be suggestive of Wilson’s
disease in asymptomatic children. The problems of measuring
24-hour copper excretion include incomplete urine collection,
and, on the other hand, copper contamination of the collection
device (this being less problematic with the advent of disposable
containers). Interpreting 24-hour urinary copper excretion can be
difﬁcult due to the overlap with ﬁndings in other types of liver
disease (e.g. autoimmune hepatitis, chronic active liver disease
or cholestasis and in particular during acute hepatic failure of
any origin). Heterozygotes may also have higher copper excretion
than controls, rarely exceeding the normal range levels [57].
Urinary copper excretion with D-penicillamine administration
was thought to be a useful diagnostic test. This test has only been
standardized in a pediatric population in which 500 mg of D-pen-
icillamine was administered orally at the beginning and again
12 h later during the 24-hour urine collection, irrespective of
body weight [58]. Compared with a spectrum of other liver dis-
eases, including autoimmune hepatitis, primary sclerosing cho-
langitis, and acute liver failure, a clear differentiation was found
when more than 25 lmol/24 h was excreted. A reassessment of
this test in paediatric patients reconﬁrmed the value in the diag-
nosis of Wilson’s disease with active liver disease, but was unre-
liable to exclude the diagnosis in asymptomatic siblings [59]. In676 Journal of Hepatology 201comparison to children with other liver diseases, the D-penicilla-
mine test had only a sensitivity of 12.5%. However, data by Dha-
wan et al. and by Nicastro et al. now suggest that using a lower
threshold for urinary copper excretion (without D-penicillamine
stimulation) of only 0.64 lmol/24 h increases sensitivity of the
test and eliminates the need for the stimulation testing with
D-penicillamine [41,45].
The penicillamine challenge test has been used in adults, but
many of the reported results of this test utilized different dosages
and timing for administration of the D-penicillamine [12,53,56].
Thus, this test is not recommended for diagnosis of Wilson’s dis-
ease in adults.
Hepatic parenchymal copper concentration
Hepatic copper accumulation is the hallmark of Wilson’s disease.
However, speciﬁc stains like rhodamine or orcein reveal focal cop-
per stores in less than 10% of patients because they detect only
lysosomal copper depositions. Thus, hepatic copper overload can-
not be excluded by histochemical evaluation of a liver biopsy
alone. Therefore, themeasurement of hepatic parenchymal copper
concentration is themethod of choice for the diagnosis ofWilson’s
disease. Biopsies for quantitative copper determination should be
placed dry in a copper-free container. Shipment for quantitative
copper determination does not require special precautions like
freezing. In general, the accuracy of measurement is improved
with adequate specimen size: at least 1 cm of biopsy core length
should be submitted for analysis [62]. Parafﬁn-embedded speci-
mensmayalso be analyzed for copper content, butmaybe less reli-
able if the specimen is small.Hepatic copper content>4 lmol/gdry
weight is considered as the best biochemical evidence forWilson’s
disease. Lowering the threshold from 4 lmol/g dry weight to
1.2 lmol/g dry weight improved sensitivity from 83.3% to 96.5%,
while speciﬁcity remained acceptable (95.4% vs. 98.6%) [28]. The
major problem with hepatic parenchymal copper concentration
is the inhomogeneous distribution of copper within the liver in
later stages of Wilson’s disease. Thus, the concentration can be
underestimated due to sampling error. In about 18% of adult
patients, hepatic copper concentrations are only between 0.8 and
4 lmol/g dry weight with a few even in the normal range [28]. In
a pediatric study, sampling error was sufﬁciently common to ren-
der this test unreliable in patients with cirrhosis [60]. On the other
hand, in long-standing cholestatic disorders, hepatic copper con-
tent may also be increased. Markedly elevated levels of hepatic
coppermayalso be found in idiopathic copper toxicosis syndromes
such as Indian childhood cirrhosis [61].
Liver histology
For diagnostic purposes, a liver biopsy is only required if the clin-
ical signs and noninvasive tests do not allow a ﬁnal diagnosis or if
there is suspicion of other or additional liver pathologies [62].
The earliest histologic abnormalities in the liver include mild
steatosis (both microvesicular and macrovesicular), glycogenated
nuclei in hepatocytes, and focal hepatocellular necrosis [62,63].
Frequently, these changes are misdiagnosed as nonalcoholic fatty
liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). The
liver biopsy may show classic histologic features of autoimmune
hepatitis (the so-called ‘‘chronic active hepatitis’’ picture). With
progressive parenchymal damage, ﬁbrosis and subsequently
cirrhosis develop. About half of the patients have cirrhosis at the2 vol. 56 j 671–685
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time of diagnosis [28]. There are a few older patientswithWilson’s
disease who do not have cirrhosis or even signs of liver disease
[5,12]. In the setting of acute liver failure due to Wilson’s disease,
there is a marked hepatocellular degeneration and parenchymal
collapse, typically on the background of cirrhosis. Apoptosis of
hepatocytes is a prominent feature during the acute injury [64].
Detection of copper in hepatocytes by routine histochemical
evaluation is highly variable. Especially in early stages of the dis-
ease, copper is mainly present in the cytoplasm bound to metal-
lothionein and is not histochemically detectable [65]. The
amount of copper varies from nodule to nodule in the cirrhotic
liver and may vary from cell to cell in pre-cirrhotic stages. The
absence of histochemically identiﬁable copper does not exclude
Wilson’s disease. Lysosomal copper complexes can be stained
by various methods, including the rhodanine or orcein stain.
Ultrastructural analysis of liver specimens at the time steato-
sis is present reveals speciﬁc mitochondrial abnormalities [66].
Typical ﬁndings include variability in size and shape, increased
density of the matrix material, and numerous inclusions includ-
ing lipid and ﬁne granular material that may be copper. The most
striking alteration is increased intracristal space with dilatation
of the tips of the cristae, creating a cystic appearance [66]. In
the absence of cholestasis, these changes are considered to be
essentially pathognomonic of Wilson’s disease. At later stages
of the disease, dense deposits within lysosomes are present.
Ultrastructural analysis may be a useful adjunct for diagnosis.
Neurologic ﬁndings and radiologic imaging of the brain
Neurologic evaluation should be performed also on patients with
presymptomatic and hepatic Wilson’s disease. Consultation
with a neurologist should be sought for evaluation of patients
with evident neurologic symptoms before treatment or soon after
treatment is initiated.
Neurologic disease may manifest as motor abnormalities with
Parkinsonian characteristics of dystonia, hypertonia and rigidity,
choreic or pseudosclerotic, with tremors and dysarthria. Due to
the great variability of neurological signs, differences in their
severity and concomitant presence of different signs in one
patient, clinical description is very difﬁcult. There is not yet a
commonly accepted scale which describes neurological signs
and their severity. One recent proposal is the Uniﬁed Wilson’s
disease Rating Scale (UWDRS) [67,68].
Magnetic resonance imaging (MRI) or computerized tomogra-
phy of the brain may detect structural abnormalities in the basal
ganglia [69]. The most frequent ﬁndings are an increased density
on computerized tomography or hyperintensity on T2 MRI in the
region of the basal ganglia.MRImay bemore sensitive in detecting
these lesions. Abnormal ﬁndings are not limited to this region, and
other abnormalities have been described. A characteristic ﬁnding
inWilson’s disease is the ‘‘face of the giant panda’’ sign [70,71], but
is found only in a minority of patients. Besides this sign, hyperin-
tensities in tectal-plate and central pons (CPM-like), and simulta-
neous involvement of basal ganglia, thalamus, and brainstem are
virtually pathognomonic of Wilson’s disease [72]. Signiﬁcant
abnormalities on brain imagingmay even be present in some indi-
viduals prior to the onset of symptoms [69].
Other neuroimaging techniques as magnetic resonance spec-
troscopy [70] and single-photon emission computed tomography
(SPECT) might be useful in detecting early brain damage in
Wilson’s disease, not only in the perspective of assessing andJournal of Hepatology 201treating motor impairment but also in better evaluating the less
investigated disorders in the cognitive domain [73]. Transcranial
brain parenchyma sonography (TCS) detects lenticular nucleus
hyperechogenicity even when in MRI no abnormalities are
observed [74], but it must be conﬁrmed in further studies [75].
Auditory-evoked brainstem potentials are helpful to docu-
ment the degree of functional impairment and the improvement
by treatment [76,77].
Genetic testing
Direct molecular-genetic diagnosis is difﬁcult because of more
than 500 possible mutations; except for a few more frequent
mutations, each of which is rare [78]. Furthermore, most patients
are compound heterozygotes (i.e. carry two different mutations).
Comprehensive molecular-genetic screening takes several
months, which makes this an impractical method. Nevertheless,
it is reasonable to perform molecular analysis of the ATP7B gene
in any patient who has a provisional diagnosis of Wilson’s dis-
ease, both for conﬁrmation purposes and to facilitate the subse-
quent screening of family members.
By contrast, allele-speciﬁc probes allow direct identiﬁcation of
a mutation and this can be rapid and clinically very helpful. How-
ever, this can only be accomplished if amutation occurswith a rea-
sonable frequency in the population (e.g. H1069Q in Central
Europe [79], –441/–427 del. in Sardinia [80,81], R778L in the Far
East [82–84]). In those cases, identiﬁcation of a mutation can sup-
port the diagnosis, while identiﬁcation of two mutations will con-
ﬁrm the diagnosis. With the advancement of DNA-based
diagnostics, such as the development of a single chip that is able
to identify the most common mutations, these recommendations
may change.
Acute liver failure due to Wilson’s disease
The most challenging aspect is the diagnosis of acute liver failure
due to Wilson’s disease, since mortality without emergency liver
transplantation is very high. Readily available laboratory tests,
including alkaline phosphatase (AP), bilirubin, and serum amino-
transferases, provide the most rapid and accurate method for
diagnosis of acute liver failure due to Wilson’s disease [85]. Com-
bination of an AP elevation/total bilirubin elevation ratio <4 and
an AST:ALT ratio >2.2 yielded a diagnostic sensitivity and speci-
ﬁcity of 100% [86]. However, these ﬁndings were challenged by
other authors. Therefore, these parameters should be considered
in case acute Wilson’s disease is suspected, but should be used in
combination with other signs and symptoms suggesting Wilson’s
disease. The combination of clinical symptoms and the conven-
tional Wilson’s disease diagnostic parameters (ceruloplasmin,
serum or urinary copper) are less sensitive and speciﬁc but
important for the diagnosis [86]. The diagnosis has to be ascer-
tained by liver biopsy if possible or at least after transplantation
(hepatic copper content, mutation analysis) to enable screening
of asymptomatic siblings.Family screening
It is essential to screen the family of patients presenting withWil-
son’s disease because the chance of a sibling being a homozygote –
and therefore developing clinical disease – is 25%. Amongst off-2 vol. 56 j 671–685 677
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spring, the chance is 0.5%. Although this risk is low, analysis of
the ATP7B gene for mutations in the children of an index patient
is justiﬁed given the potential devastating course of Wilson’s dis-
ease. There is difﬁculty in diagnosing heterozygote carriers with
certainty, but siblings of an index case with a documented muta-
tion can be screened by mutational analysis.
If the mutation(s) of the index case are not detected, pedigree
analysis using haplotypes based on polymorphisms surrounding
the Wilson’s disease gene is available. This analysis requires the
identiﬁcation of an index patient with the unquestionable diag-
nosis of Wilson’s disease within the family. DNA is required from
both parents. Then the haplotype, based on the pattern of dinu-
cleotide and trinucleotide repeats around ATP7B, is determined
in the index patient and his/her family. The inheritance of the
‘‘disease-associated’’ haplotypes allows determining whether
they are unaffected, heterozygous, or indeed patients [78].
Genetic testing is the only reliable method to separate heterozy-
gote from homozygote siblings.Treatment
A number of drugs are available for the treatment of Wilson’s dis-
ease, including D-penicillamine, trientine, zinc, tetrathiomolyb-Recommendation 1
• Wilson’s disease should be considered in any individual 
with liver abnormalities or neurological movement 
disorders of uncertain cause. Age alone should not be 
the basis for eliminating a diagnosis of Wilson’s disease 
GRADE II-2, A, 1
AASLD Class I, Level B
• Wilson’s disease must be considered in any patient 
with unexplained liver disease in combination with 
neurological or neuropsychiatric disorders 
GRADE II-2, A, 1
AASLD Class I, Level B
• Kayser-Fleischer rings should be sought by slit-lamp 
examination by a skilled examiner. The absence of 
Kayser-Fleischer rings does not exclude the diagnosis 
of Wilson’s disease, even in patients with predominantly 
neurological disease 
GRADE II-2, A, 1
AASLD Class I, Level B
• Neurologic evaluation and imaging of the brain, 
preferably by MR imaging, should be considered prior to 
treatment in all patients with neurologic Wilson’s disease 
and should be part of the evaluation of any patient 
presenting with neurological symptoms consistent with 
Wilson’s disease
GRADE II-2, B, 1
AASLD Class I, Level C
678 Journal of Hepatology 201date, and dimercaprol. Once the diagnosis has been made,
treatment needs to be life-long. There is a lack of high-quality
evidence to estimate the relative treatment effects of the avail-
able drugs in Wilson’s disease. Therefore, multicentre prospective
randomized controlled comparative trials are necessary [87].
D-Penicillamine
The major effect of D-penicillamine in Wilson’s disease is to
promote the urinary excretion of copper. D-penicillamine may
also act by inducing metallothionein [88]. The maintenance
dose is usually 750–1500 mg/day administered in two or three
divided doses. Dosing in children is 20 mg/kg/day rounded off
to the nearest 250 mg and given in two or three divided doses.
D-Penicillamine is best administered 1 h prior to meals, because
food inhibits its absorption. Since D-penicillamine tends to
interfere with pyridoxine action, supplemental pyridoxine
should be provided (25–50 mg/day). D-penicillamine interferes
with collagen cross-linking [89] and has some immunosuppres-
sant actions [90,91].
Adequacy of treatment can be monitored by measuring 24-
hour urinary copper excretion while on treatment. This is highest
immediately after starting treatment and may exceed 16 lmol
(1000 lg) per 24 h at that time. For long-term treatment, the• A low serum ceruloplasmin level should be taken 
as evidence for the diagnosis of Wilson’s disease. 
Borderline levels require further evaluation. Serum 
ceruloplasmin within the normal range does not 
necessarily exclude the diagnosis 
GRADE II-2, A, 1
AASLD Class I, Level B
• Basal 24-hour urinary excretion of copper >1.6 µmol 
is typical in symptomatic patients. In children with mild 
hepatic disease basal 24-hour urinary excretion of 
copper can only be mildly elevated or may even be 
in the normal range. Lowering the threshold to 
>0.64 µmol/24 hr may be useful for detecting 
asymptomatic patients but this will be less sensitive and 
will overlap with patients with other liver injury 
GRADE II-2, B, 1
AASLD Class I, Level C
• Hepatic parenchymal copper content >4 µmol/g dry 
weight provides critical diagnostic information and 
should be obtained in cases where the diagnosis is not 
straightforward and in younger patients. In untreated 
patients, normal hepatic copper content 
(<0.64-0.8 µmol/g dry weight) almost always excludes a 
diagnosis of Wilson’s disease
GRADE III, B, 2
AASLD Class I, Level B
• 
whole-gene sequencing is currently possible and 
haplotype analysis should be the primary mode for 
Wilson’s disease
GRADE II-2, B, 1
AASLD Class I, Level B
Mutation analysis with specific allelic probes or by
available. Specific testing for known mutations or
screening of first-degree relatives of patients with
2 vol. 56 j 671–685
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most important sign of efﬁcacy is a maintained clinical and labo-
ratory improvement. Serum ceruloplasmin may decrease after
initiation of treatment. Urinary copper excretion should run in
the vicinity of 3–8 lmol per 24 h on treatment. To document
therapeutic efﬁciency, urinary copper excretion after 2 days of
D-penicillamine cessation should be 61.6 lmol/24 h. In addition,
the estimate of non-ceruloplasmin bound copper shows normal-
ization of non-ceruloplasmin bound copper concentration with
effective treatment [92]. Values of urine copper excretion
>1.6 lmol/24 h after two days of D-penicillamine cessation may
indicate non-adherence to therapy (in those patients non-cerulo-
plasmin-bound copper is elevated >15 lg/L).
D-penicillamine is rapidly absorbed from the gastrointestinal
tract with a double-peaked curve for intestinal absorption
[93,94]. If D-penicillamine is taken with a meal, its absorption
is decreased overall by about 50%. Once absorbed, 80% of
D-penicillamine circulates bound to plasma proteins. Greater
than 80% of D-penicillamine excretion is via the kidneys. The
excretion half-life of D-penicillamine is on the order of 1.7–7 h,
but there is considerable inter-individual variation.
Numerous studies attest to the effectiveness of D-penicilla-
mine as treatment for Wilson’s disease [95–97]. In patients with
symptomatic liver disease, recovery of synthetic liver function
and improvement in clinical signs occur typically during the ﬁrst
2–6 months of treatment, but further recovery can occur during
the ﬁrst year of treatment. Failure to comply with therapy leads
to signiﬁcant progression of liver disease and liver failure within
1–12 months following discontinuation of treatment.
In patients with neurologic Wilson’s disease, improvement of
symptoms is slower and may be observed even after three years
[97]. Worsening of neurologic symptoms has been reported in
10–50% of patients treated with D-penicillamine during the initial
phase of treatment. In a recent series, neurologic worsening
occurred on all three treatments used for Wilson’s disease (D-
penicillamine, trientine, zinc), but mainly with D-penicillamine,
where 13.8% were adversely affected [27]. Tolerability of D-
penicillamine may be enhanced by starting with incremental
doses, 125–250 mg/day increased by 250 mg increments every
4–7 days to amaximumof 1000–1500 mg/day in 2–4 divided dos-
ages. Administration of doses 1500 mg per day or higher at once
may lead to rapid andoften irreversible neurological deterioration.
Rapid re-administration of the treatment in patients who stopped
it for longer time may also evoke irreversible neurological signs.
D-penicillamine is associated with numerous side effects.
Severe side effects requiring the drug to be discontinued occur
in approximately 30% of patients [95,98]. Early sensitivity reac-
tions marked by fever and cutaneous eruptions, lymphadenopa-
thy, neutropenia or thrombocytopenia, and proteinuria may
occur during the ﬁrst 1–3 weeks.
Signiﬁcant bone marrow toxicity includes severe thrombocy-
topenia or total aplasia. In these conditions, D-penicillamine
should be discontinued immediately. Late reactions include
nephrotoxicity, usually heralded by proteinuria or the appear-
ance of other cellular elements in the urine, for which discontin-
uation of D-penicillamine should be immediate. Other late
reactions include a lupus-like syndrome marked by hematuria,
proteinuria, and positive antinuclear antibody, and with higher
dosages of D-penicillamine no longer typically used for treating
Wilson’s disease, Goodpasture syndrome. Dermatological toxici-
ties reported include progeric changes in the skin and elastosis
perforans serpingosa [99], and pemphigous or pemphigoidJournal of Hepatology 201lesions, lichen planus, and aphthous stomatitis. Very late side
effects are rare and include nephrotoxicity, myasthenia gravis
[100], polymyositis, loss of taste, immunoglobulin A depression,
and serous retinitis. Hepatic siderosis has been reported in trea-
ted patients with reduced levels of serum ceruloplasmin and
non-ceruloplasmin bound copper [101]. Overtreatment with pen-
icillamine may lead to a reversible sideroblastic anemia and
hemosiderosis.
Trientine
Trientine (triethylene tetramine dihydrochloride or 2,2,2-tetra-
mine) was introduced in 1969 as an alternative to D-penicilla-
mine. Trientine is a chelator with a polyamine-like structure
chemically distinct from D-penicillamine. It lacks sulfhydryl
groups and copper is chelated by forming a stable complex with
the four constituent nitrogens in a planar ring. Like D-penicilla-
mine, trientine promotes urinary copper excretion.
Few data exist about the pharmacokinetics of trientine. It is
poorly absorbed from the gastrointestinal tract, and what is
absorbed is metabolized and inactivated [102]. About 1% of
the administered trientine and about 8% of the biotransformed
trientine metabolite, acetyltrien, ultimately appear in the urine.
The amounts of urinary copper, zinc and iron increase in par-
allel with the amount of trientine excreted in the urine
[103]. The potency of trientine as copper chelator in compari-
son to D-penicillamine is controversial [95,104]. Trientine and
D-penicillamine may mobilize different pools of body copper
[105].
Typical dosages of trientine are 900–2700 mg/day in two or
three divided doses, with 900–1500 mg/day used for mainte-
nance therapy. In children, the weight-based dose is not estab-
lished, but the dose generally used is 20 mg/kg/day rounded off
to the nearest 250 mg, given in two or three divided doses. Trien-
tine should be administered 1 h before or 3 h after meals. Taking
it closer to meals is acceptable if this ensures compliance. Trien-
tine tablets may not be stable for prolonged periods at high ambi-
ent temperature, which is a problem for patients travelling to
warm climates.
Trientine is an effective treatment for Wilson’s disease
[106,107]. Trientine, while being developed for use in patients
who are intolerant of penicillamine, has also been shown to be
an effective initial therapy, even with patients with decompen-
sated liver disease at the outset [108,109]. In general, adverse
effects due to D-penicillamine resolve when it is substituted for
trientine and do not recur during prolonged treatment with
trientine.
Neurological worsening after beginning of treatment with tri-
entine has been reported but appears less common than with D-
penicillamine. Trientine also chelates iron, and co-administration
of trientine and iron should be avoided because the complex with
iron is toxic. A reversible sideroblastic anemia may be a
consequence of overtreatment and resultant copper deﬁciency.
Lupus-like reactions have also been reported in some Wilson’s
disease patients treated with trientine. However, these patients
were almost all uniformly treated previously with D-penicilla-
mine, so the true frequency of this reaction when trientine is used
de novo is unknown.
Adequacy of treatment is monitored by measuring 24-hour
urinary copper excretion (after 2 days of cessation of therapy)
and by measuring non-ceruloplasmin bound copper.2 vol. 56 j 671–685 679
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Ammonium tetrathiomolybdate
Ammonium tetrathiomolybdate (TM) is a very strong decoppering
agent. TMcomplexeswith copper; in the intestinal tract it prevents
absorption, and in the circulation renders copper unavailable for
cellular uptake [110]. TM can directly and reversibly down-regu-
late copper delivery to secreted metalloenzymes [111]. At low
doses, TM removes copper from metallothionein, but at higher
doses it forms an insoluble copper complex, which is deposited
in the liver [112]. TM remains an experimental therapy, and it is
not commercially available. As yet, clinical experience with this
drug is limited. The control of free copper was prospectively stud-
ied as initial anti-copper treatment in neurologically presenting
Wilson’s disease patients [113]. Patients were treated for 8 weeks
with TM, and thereafter with zinc. In an open-label trial, TM
showed very strong control of free copper levels. In a double-blind
trial, TM signiﬁcantly better controlled free copper levels than tri-
entine. On trientine, ﬁve patientsworsenedneurologically and this
was associated with signiﬁcant spikes in serum free copper levels.
Other data also indicate its utility because it may less likely cause
neurological deterioration [114,115]. Potential adverse effects
include bone marrow depression [116], hepatotoxicity [117], and
overly aggressive copper removal, which causes neurological dys-
function. TM also has anti-angiogenic effects due to its extensive
decoppering effect [118].
Zinc
Zinc was ﬁrst used to treat Wilson’s disease by Schouwink in
Holland in the early 1960s [119]. Its mechanism of action is dif-
ferent from that of penicillamine and trientine: zinc interferes
with the uptake of copper from the gastrointestinal tract. Zinc
induces enterocyte metallothionein, a cysteine-rich protein that
is an endogenous chelator of metals. Metallothionein has greater
afﬁnity for copper than for zinc and, thus, preferentially binds
copper present in the enterocyte and inhibits its entry into the
portal circulation. Once bound, the copper is not absorbed but
is lost into the fecal contents as enterocytes are shed by normal
turnover [120]. Because copper also enters the gastrointestinal
tract from saliva and gastric secretions, zinc treatment can
generate a negative balance for copper and thereby remove
stored copper [121,122]. Zinc may also act by inducing levels of
hepatocellular metallothionein [123,124], thus binding excess
of toxic copper to prevent hepatocellular injury.
Different zinc salts (sulphate, acetate, gluconate) are used. The
recommended dose is 150 mg elemental zinc/day (for children
<50 kg in body weight 75 mg) administered in three divided
doses, 30 min before meals. Whether a combination therapy with
chelators has advantages is not yet known. However, to avoid the
neutralization of zinc efﬁciency by chelators, different times of
dosing have to be considered. The compliance with the three
times per day dosage may be problematic. The zinc salt used does
not make a difference with respect to efﬁcacy but may affect tol-
erability. Taking the zinc medication with food interferes with its
absorption [125]. Adequacy of treatment with zinc is judged by
clinical and biochemical improvement and by measuring 24-hour
urinary excretion of copper, which should be less than 1.6 lmol
per 24 h on stable treatment. Additionally, non-ceruloplasmin-
bound copper should drop with effective treatment. Urinary
excretion of zinc may be measured from time to time to check
compliance.680 Journal of Hepatology 201Zinc has few side effects. Gastric irritation is a common prob-
lem and may be dependent on the salt employed. Zinc may have
immunosuppressant effects and reduce leukocyte chemotaxis.
Elevations in serum lipase and/or amylase may occur, without
clinical or radiologic evidence of pancreatitis. Neurological dete-
rioration is uncommon with zinc [96,126,127]. Whether high-
dose zinc is safe for patients with impaired renal function is
not yet established.
Most data on zinc come from uncontrolled studies of dosages
ranging from 75 to 250 mg per day [87,128]. Zinc is probably less
effective than chelating agents in the treatment of established
Wilson’s disease, although data are limited and uncontrolled
[129]. Although zinc is currently reserved for maintenance treat-
ment, it has also been used as ﬁrst-line therapy, most commonly
for asymptomatic or presymptomatic patients. It appears to be
equally effective as D-penicillamine but better tolerated [96].
Reports of large studies in adults with Wilson’s disease indicate
good efﬁcacy [122]. While zinc monotherapy appears to be effec-
tive and safe in neurologic Wilson’s disease and in asymptomatic
siblings, great caution is needed in patients with hepatic Wilson’s
disease. Hepatic deterioration has been occasionally reported
when zinc was commenced and was fatal in one case [127]. Thus,
exclusive monotherapy with zinc in symptomatic Wilson’s liver
disease is controversial. In the Netherlands, 17 symptomatic
patients with Wilson’s disease were treated with zinc only with
a median follow-up of 14 years [128]. The outcome of exclusive
zinc therapy was generally good in cases of neurologic disease.
A less satisfactory outcome in hepatic disease may relate to less
efﬁcient de-coppering. Two patients with hepatic Wilson’s dis-
ease progressed to a decompensated state and two patients with
neurologic Wilson’s disease developed symptomatic liver disease.
Long-term outcomes of different treatments in 288 German and
Austrian Wilson’s disease patients indicated that, in the majority
of patients, treatment with chelating agents or zinc salts was
effective. However, there was an advantage for chelating agents
to prevent hepatic deterioration [129]. In contrast, in a Polish
cohort of 164 patients there were no differences in survival of
patients who started therapy with zinc sulfate or D-penicillamine
[38]. Current guidelines recommend that all symptomatic
patients with Wilson disease should receive a chelating agent
(penicillamine or trientine) [130,131]. Zinc may have a role as a
ﬁrst line therapy in neurological patients.
Other treatments
Antioxidants, mainly vitamin E, may have a role as adjunctive
treatment [132,133]. Serum and hepatic vitamin E levels have
been found to be low in Wilson’s disease [134–136]. Symptom-
atic improvement when vitamin E was added to the treatment
regimen has been occasionally reported but no rigorous studies
have been conducted. One study suggests no correlation of anti-
oxidant deﬁciency with clinical symptoms [135].
Animal data suggest a role for amitriptyline in impending liver
failure due to Wilson’s disease, as it reduces the copper-induced
apoptosis of liver cells, and thereby increases survival of ATP7B-
deﬁcient rats [137]. However, no human data are available yet.
In vitro, treatment with pharmacological chaperones 4-
phenylbutyrate and curcumin, partially restored protein expres-
sion of most ATP7B mutants and might enable novel treatment
strategies in Wilson’s disease, by directly enhancing the protein
expression of mutant ATP7B with residual copper export activity2 vol. 56 j 671–685
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[138]. Furthermore, curcumin is an ideal antioxidant and an
effective scavenger of reactive oxygen species [139] and can act
as a copper-chelating agent [140]. Clinical data in patients with
Wilson’s disease are not yet available.
Liver transplantation
Transplantation is frequently necessary for patients presenting
with acute liver failure or decompensated cirrhosis due to
Wilson’s disease [141]. Because the biochemical defect resides
mainly in the liver, orthotopic liver transplantation (OLT) cor-
rects the underlying problem. Schilsky analyzed 55 transplants
performed in 33 patients with decompensated cirrhosis and 21
with acute liver failure due to Wilson’s disease in the United
States and Europe [142]. The median survival after OLT was
2.5 years, the longest survival time after OLT was 20 years.
Survival at 1 year was 79%. Nonfatal complications occurred
in ﬁve patients. Fifty-one OLT were performed on 39 patients
(16 pediatric, 23 adults) at the University of Pittsburgh
[143]. The rate of primary graft survival was 73% and patient
survival was 79%. Survival was better for those with a chronic
advanced liver disease presentation (90%) than it was for those
with an acute liver failure (73%) presentation. Living related
donor transplantation (where the donor is an obligate hetero-Recommendation 2
• Initial treatment for symptomatic patients with 
Wilson’s disease should include a chelating agent 
(D-penicillamine or trientine). Trientine may be better 
tolerated
GRADE II-1, B, 1
AASLD Class I, Level B 
• Zinc may have a role as a  line therapy in neurological 
patients 
GRADE II-2, C, 2
AASLD Class II, Level C
• Treatment of presymptomatic patients or those with 
neurological disease on maintenance therapy can be 
accomplished with a chelating agent or with zinc 
GRADE II-1, B, 1
AASLD Class I, Level B
• Treatment is lifelong and should not be discontinued, 
unless liver transplantation is performed 
GRADE II-1, B, 1
AASLD Class I, Level B
• If zinc is used, careful monitoring of transaminases is 
needed, with changing to chelators if these laboratory 
parameters are increasing 
GRADE C1
AASLD Class I, Level B
• Patients should avoid intake of foods and water with high 
concentrations of copper, especially during the  year 
of treatment 
GRADE II-3, B, 2
AASLD Class I, Level C
first
first
Journal of Hepatology 201zygote) is feasible and gives excellent results [144–146]. Sur-
vival is satisfactory and appears to be better for patients
having a transplant for chronic advanced liver disease than
for those with acute liver failure. Overall survival is improving;
the longest recorded survival is 20 years. A limited observation
suggests that the neurologic symptoms of patients who need
OLT may also improve as a result [145]. However, severe neu-
rological deterioration was also observed after successful OLT
[147].Pregnancy
Successful treatment means that women with Wilson’s disease
can become pregnant [148,149]. Counseling should indicate that
the likelihood of ﬁnding a homozygote amongst children is
0.5%; haplotype analysis of the partner is justiﬁed. The patient’s
copper status should be optimized prior to pregnancy. Although
there is some concern over the teratogenicity of D-penicilla-
mine, the risks of withdrawing treatment outweigh those of
continuing it. A compilation of published case series on 161
pregnancies in 83 women with Wilson’s disease (one of them
after successful in vitro fertilization) treated with D-penicilla-
mine during pregnancy showed 122 births with 119 normal• Patients with acute liver failure due to Wilson’s disease 
should be treated with liver transplantation when the 
revised King’s score is 11 or higher 
GRADE II-2, B, 1
AASLD Class I, Level B [41]
• Patients with decompensated cirrhosis, unresponsive to 
chelation treatment, should be evaluated promptly for 
liver transplantation  
GRADE II-2, B, 1
AASLD Class I, Level B
• Treatment for Wilson’s disease should be continued 
during pregnancy, but dosage reduction is advisable for 
D-penicillamine and trientine 
GRADE II-3, B, 1
AASLD Class I, Level C
• For routine monitoring, serum copper and ceruloplasmin, 
liver enzymes and international normalized ratio, 
functional parameters, complete blood count and 
urine analysis as well as physical and neurological 
examinations should be performed regularly, at least 
twice annually 
GRADE II-2, B, 1
AASLD Class I, Level C
• The 24-hour urinary copper excretion on medication and 
after 2 days of cessation of therapy should be measured 
at least yearly. The estimated serum non-ceruloplasmin-
bound copper may be another useful parameter to 
control therapy 
GRADE II-3, B, 1
AASLD Class I , Level C
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newborns [150]. A high abortion rate was only observed in a
study from India [151].
This is also true for treatment with trientine [152] or zinc
[149]. Whether the dose of a chelator should be lowered or
not is based on speculations rather than data. The highest risk
for fetal teratogenicity is in the ﬁrst trimester, therefore
lowering D-penicillamine during the ﬁrst trimester was rec-
ommended with continued monitoring on the lower dosage
for all trimesters [130]. Others recommended reducing the
chelators to a minimal dose, i.e. 300–600 mg/day in the last
trimester in order to avoid insufﬁcient copper supply to the
fetus or insufﬁcient wound healing after Cesarean section or
episiotomy [148]. Breast feeding under chelation therapy is
not recommended, although there are reports that children
breast fed by mothers on D-penicillamine had no problems
[153].
Although contraception is an important issue, no detailed
studies were performed so far. Estrogens may interfere with bil-
iary copper excretion. In healthy women taking contraceptives,
serum copper and urinary copper excretion increased [154], even
corneal copper depositions were observed [155]. Many intrauter-
ine devices contain copper. Thus, only spermicide and barrier
contraceptives and progesterone-only preparations can be safely
prescribed [156].Disclosures
The contributors to these Clinical Practice Guidelines have indi-
cated that they have no relationships with commercial entities
that might be perceived as having connection with this
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